The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis

被引:24
作者
Matsumoto, Yukihiro [1 ,2 ]
Murat, Dogru [3 ]
Kojima, Takashi [2 ]
Shimazaki, Jun [2 ,3 ]
Tsubota, Kazuo [2 ]
机构
[1] Keio Univ, Johnson & Johnson Dept Ocular Surface & Visual Op, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan
[3] Tokyo Dent Coll, Dept Ophthalmol, Chiba, Japan
关键词
IN-SITU KERATOMILEUSIS; ANTIFUNGAL AGENT; PENETRATING KERATOPLASTY; MICROBIAL KERATITIS; ECHINOCANDIN ANTIFUNGALS; ESOPHAGEAL CANDIDIASIS; RESISTANT CANDIDA; CLINICAL-EFFICACY; DOUBLE-BLIND; SPECTRUM;
D O I
10.1136/bjo.2010.191734
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim To compare and evaluate the efficacy of topical 0.1% micafungin (MCFG) and topical 0.2% fluconazole (FCZ) in the treatment of Candida fungal keratitis. Methods Twenty-nine eyes of 29 patients who were diagnosed as having Candida fungal keratitis, proven by corneal culture isolates, were investigated in this prospective study. Patients were divided into a MCFG treatment group (12 eyes) and an FCZ treatment group (17 eyes). Age, gender, initial status of ulcer (ulcer size and degree of injection), initial and final best-corrected visual acuity (BCVA), healing periods, final status of cornea and recurrences in each group were studied and compared. Results There were no significant differences in relation to age, gender, ulcer size and degree of injection before treatment between the two groups. There were also no significant differences in the healing periods until complete epithelialisation (MCFG treatment group (41.3 +/- 38.0 days); FCZ treatment group (34.4 +/- 37.7 days)), change in BCVA, corneal clarity/opacification, perforation and recurrence status at the final examination between the two groups. Conclusion The efficacy of 0.1% MCFG eye-drops appears to be comparable with that of 0.2% FCZ eye-drops in the treatment of Candida fungal keratitis.
引用
收藏
页码:1406 / 1409
页数:4
相关论文
共 40 条
[1]   Clinical efficacy of echinocandin antifungals [J].
Arathoon, EG .
CURRENT OPINION IN INFECTIOUS DISEASES, 2001, 14 (06) :685-691
[2]   MICROBIAL KERATITIS AFTER PENETRATING KERATOPLASTY [J].
BATES, AK ;
KIRKNESS, CM ;
FICKER, LA ;
STEELE, ADM ;
RICE, NSC .
EYE, 1990, 4 :74-78
[3]   TOPICAL FLUCONAZOLE FOR EXPERIMENTAL CANDIDA KERATITIS IN RABBITS [J].
BEHRENSBAUMANN, W ;
KLINGE, B ;
RUCHEL, R .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1990, 74 (01) :40-42
[4]   Effects of methylprednisolone and cyclosporine A on fungal growth in vitro [J].
Bell, NP ;
Karp, CL ;
Alfonso, EC ;
Schiffman, J ;
Miller, D .
CORNEA, 1999, 18 (03) :306-313
[5]   Candida parapsilosis keratitis [J].
Bourcier, T ;
Touzeau, O ;
Thomas, F ;
Chaumeil, C ;
Baudrimont, M ;
Borderie, V ;
Laroche, L .
CORNEA, 2003, 22 (01) :51-55
[6]   AMPHOTERICIN-B - CURRENT UNDERSTANDING OF MECHANISMS OF ACTION [J].
BRAJTBURG, J ;
POWDERLY, WG ;
KOBAYASHI, GS ;
MEDOFF, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (02) :183-188
[7]   A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients [J].
de Wet, N ;
Llanos-Cuentas, A ;
Suleiman, J ;
Baraldi, E ;
Krantz, EF ;
Della Negra, M ;
Diekmann-Berndt, H .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (06) :842-849
[8]   A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis [J].
de Wet, NTE ;
Bester, AJ ;
Viljoen, JJ ;
Filho, F ;
Suleiman, JM ;
Ticona, E ;
Llanos, EA ;
Fisco, C ;
Lau, W ;
Buell, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (07) :899-907
[9]   Echinocandin antifungal drugs [J].
Denning, DW .
LANCET, 2003, 362 (9390) :1142-1151
[10]  
FONG LP, 1988, OPHTHALMOLOGY, V95, P1269